Stempoint Capital LP Makes New $1.47 Million Investment in Sionna Therapeutics, Inc. $SION

Stempoint Capital LP bought a new stake in Sionna Therapeutics, Inc. (NASDAQ:SION) during the 1st quarter, HoldingsChannel reports. The fund bought 36,540 shares of the company’s stock, valued at approximately $1,465,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. UBS Group AG boosted its position in shares of Sionna Therapeutics by 91.1% during the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock worth $3,669,000 after acquiring an additional 42,511 shares in the last quarter. Vanguard Group Inc. raised its position in Sionna Therapeutics by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares in the last quarter. Candriam S.C.A. bought a new stake in Sionna Therapeutics during the first quarter worth $9,494,000. Jennison Associates LLC lifted its stake in Sionna Therapeutics by 11.8% during the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after purchasing an additional 117,903 shares during the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in shares of Sionna Therapeutics in the 4th quarter valued at $26,290,000.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SION shares. Citizens Jmp reiterated a “market outperform” rating and issued a $63.00 price target on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Freedom Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Stifel Nicolaus lifted their target price on Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, May 18th. Finally, BTIG Research reissued a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a research note on Wednesday, May 13th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Sionna Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $53.22.

Insiders Place Their Bets

In other Sionna Therapeutics news, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the transaction, the director directly owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of Sionna Therapeutics stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares in the company, valued at $110,802,360.74. The trade was a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 989,630 shares of company stock worth $44,987,483 in the last 90 days. 5.10% of the stock is currently owned by corporate insiders.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock opened at $44.81 on Thursday. Sionna Therapeutics, Inc. has a fifty-two week low of $16.38 and a fifty-two week high of $51.56. The firm has a market capitalization of $2.02 billion, a P/E ratio of -23.22 and a beta of 1.33. The company’s 50 day moving average price is $41.44 and its two-hundred day moving average price is $39.92.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, analysts expect that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.